Your browser doesn't support javascript.
loading
Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.
Hamuro, Lora; Hu, Zheyi; Passarell, Julie; Barcomb, Heather; Zhang, Joshua; Goldstein, Shay; Bello, Akintunde; Roy, Amit; Zhu, Li.
Affiliation
  • Hamuro L; Bristol Myers Squibb, Princeton, New Jersey.
  • Hu Z; Bristol Myers Squibb, Princeton, New Jersey.
  • Passarell J; Cognigen Corporation, Buffalo, New York.
  • Barcomb H; Cognigen Corporation, Buffalo, New York.
  • Zhang J; Bristol Myers Squibb, Princeton, New Jersey.
  • Goldstein S; Bristol Myers Squibb, Princeton, New Jersey.
  • Bello A; Bristol Myers Squibb, Princeton, New Jersey.
  • Roy A; Bristol Myers Squibb, Princeton, New Jersey.
  • Zhu L; Bristol Myers Squibb, Princeton, New Jersey.
Clin Cancer Res ; 28(8): 1603-1613, 2022 04 14.
Article in En | MEDLINE | ID: mdl-34980597
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Kidney Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Kidney Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: United States